ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Care

Casio brings skin cancer detectors overseas, including to US

Japanese company aims to boost medical device revenue past $9m

Casio's Dermocamera takes polarized shots of lesions to help diagnose skin cancer. (Photo courtesy of Casio)

TOKYO -- Japanese electronics manufacturer Casio Computer will release its skin cancer detection devices in foreign markets, anticipating demand in countries with higher rates of the condition.

Casio will market its Dermocamera and dermoscope in Australia and New Zealand by March, expanding to Taiwan and the U.S. later this year. Australia had the highest rate of melanoma in 2018, followed by New Zealand, according to data compiled by the World Cancer Research Fund.

By taking this business overseas, Casio looks to lift revenue from medical devices north of 1 billion yen ($9.48 million) in two to three years. The segment's sales are currently estimated between 100 million yen and 200 million yen.

The two devices work by magnifying and photographing skin lesions under different lighting conditions. A physician can identify whether the lesion is a malignant tumor based on the surface structure and coloring.

The dermoscope magnifies the lesion for observation. If the doctor thinks further examination is needed, the Dermocamera is applied directly to the skin for photography and analysis.

The devices were developed in 2018 by repurposing technology from Casio's defunct consumer digital camera business. They have been available only in Japan, where the Dermocamera sells for about 200,000 yen while the dermoscope is priced at roughly 70,000 yen. Casio has sold more than 1,000 Dermocameras and over 500 dermoscopes to date.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more